Obeda vs Ozempic vs Wegovy: What's the Difference? (2026 Guide)

If you have been researching weight loss injections in India, you have almost certainly come across three names: Obeda, Ozempic, and Wegovy. They all involve the same molecule - semaglutide - but they are not identical products.

Understanding the real differences helps you have a more informed conversation with your doctor and avoid overpaying for something that may not be available or necessary.

Important: Always consult your healthcare provider before starting any medication. This article is for informational purposes only.

Availability update (October 2026): Dr. Reddy's paused supplies of the original Obeda injection in July 2026 after finding an impurity issue linked to the active ingredient, and said supply would not return before November. It has since started selling two new semaglutide brands, Obeda Pro and Obeda Plus. Obeda tablets (oral semaglutide) were not affected. Check current stock with your pharmacist, and do not change brand, pen or strength without your prescriber.

The Short Answer

All three - Obeda, Ozempic, and Wegovy - are based on semaglutide, a GLP-1 receptor agonist. The differences lie in:

• Who makes them (and where)
• What they are approved for
• The dose range
• The price

Side-by-Side Comparison

What Is Ozempic?

Ozempic is Novo Nordisk's original semaglutide product, launched for type 2 diabetes management. It became enormously popular globally when doctors and patients noticed significant weight loss as a side effect.

Novo Nordisk launched Ozempic in India in December 2025, in 0.25 mg, 0.5 mg and 1 mg doses, marketed only for type 2 diabetes. It is imported from Denmark. Its price was cut from April 2026, to about ₹5,660 to ₹9,100 a pen. It is not approved as a weight loss drug, though it is sometimes used off-label for that purpose.

What Is Wegovy?

Wegovy is also made by Novo Nordisk and contains the same semaglutide molecule, but it is approved for obesity and weight management at a higher maximum dose (2.4mg weekly, versus 1mg for Ozempic in India).

In the STEP 1 trial, adults with obesity without diabetes taking Wegovy 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. Novo Nordisk launched Wegovy in India in June 2025.

What Is Obeda?

Obeda is Dr. Reddy's Laboratories' generic semaglutide, launched in India on March 21, 2026, following the expiry of Novo Nordisk's semaglutide patent in India on March 20, 2026.

It comes as pre-filled pens: a 2 mg pen that gives 0.25 mg or 0.5 mg doses and a 4 mg pen that gives 1 mg doses. At launch it was DCGI-approved for type 2 diabetes, and Dr. Reddy's said it was seeking a weight-management approval. Dr. Reddy's paused supply of the original Obeda injection in July 2026 and has since launched Obeda Pro and Obeda Plus, so check stock with your pharmacist.

The complete Obeda guide for beginners explains the full picture of how it works and what to expect.

Why Is Obeda So Much Cheaper?

Novo Nordisk held a patent on semaglutide that prevented other companies from making it. That patent expired in India on March 20, 2026. Dr. Reddy's (and other Indian pharma companies) could then legally manufacture their own semaglutide - using the same molecule but at a fraction of the manufacturing cost.

Generic medicines in India are usually priced well below originator brands, and many generic semaglutide brands launched below Obeda's price. Novo Nordisk has since cut its own prices, so the gap has narrowed.

Does the Cheaper Price Mean Lower Quality?

Not necessarily. The DCGI, India's drug regulator, reviewed Dr. Reddy's data before approval, including a Phase III head-to-head trial in 312 people with type 2 diabetes, which found blood sugar control similar to the original medicine.

Dr. Reddy's has a strong global track record. Its products are approved by the US FDA, European EMA, and the DCGI. You are getting the same semaglutide molecule in Obeda as you would in Ozempic - the difference is the manufacturer and the price.

Which One Should You Choose?

For most Indian patients:

• If you want semaglutide for weight loss or diabetes and are in India: Obeda is the most practical and affordable option available right now.
• If you are already on Ozempic and it is working: Do not switch without consulting your doctor, but switching to Obeda is a valid option to discuss given the significant cost difference.
• If you want the higher 2.4mg weight-loss dose (Wegovy-level): Discuss this with your doctor. Obeda pens only give doses up to 1 mg, so a 2.4 mg dose needs a product approved for weight management, such as Wegovy. Never try to make up a higher dose from Obeda pens.

Knowing what to eat while taking Obeda and managing early side effects correctly will matter far more to your results than the brand name on the pen.

How Weight Easy Helps You Get Better Results

Choosing between Obeda, Ozempic, or Wegovy is one decision. Actually succeeding on semaglutide is another challenge entirely. Many people who start GLP-1 medications do not get the results they hoped for - often because they do not have the right support system.

Weight Easy is designed specifically for GLP-1 users in India. The platform gives you:

• Dietary guidance optimized for semaglutide users
• Side effect tracking and management to stay consistent
• Progress monitoring with weekly check-ins
• Expert coaching on building habits that stick

If you are starting Obeda, the right support can make a significant difference. Weight Easy helps you stay consistent, manage side effects, and achieve better results.

The Bottom Line

Obeda, Ozempic, and Wegovy contain the same molecule, with different brand names, manufacturers, approved uses, doses and price tags. Obeda and Ozempic are diabetes brands going up to 1 mg weekly; Wegovy is the weight-management brand going up to 2.4 mg.

The results depend on the dose, consistency, and lifestyle habits more than the brand.

Consult your healthcare provider before starting any medication.

Sources

• Central Drugs Standard Control Organisation (CDSCO): https://cdsco.gov.in/opencms/opencms/en/Home/
• MedicalDialogues — India semaglutide market and brand launch context: https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838
• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. https://doi.org/10.1056/NEJMoa2032183
• Dr. Reddy's Obeda injection launch, DCGI approval for type 2 diabetes, strengths and price (BioSpectrum India, March 2026): https://biospectrumindia.com/news/16/27524/dr-reddys-laboratories-announces-launch-of-dcgi-approved-semaglutide-injection-obeda-for-type-2-diabetes.html
• Obeda injection supply pause and launch of Obeda Pro and Obeda Plus (India Weekly, October 2026): https://www.indiaweekly.biz/dr-reddys-launches-two-new-semaglutide-brands-after-obeda-injection-supply-disruption/
• Novo Nordisk India price cut for Ozempic and Wegovy from April 2026 (BioSpectrum India): https://biospectrumindia.com/news/16/27598/novo-nordisk-india-sets-patient-centred-price-of-rs-202-day-for-starting-dose-of-ozempic-and-wegovy.html
• Ozempic and Wegovy India price ranges after the cut (Outlook Business, March 2026): https://www.outlookbusiness.com/corporate/novo-nordisk-cuts-ozempic-wegovy-prices-by-up-to-48-amid-generic-pressure
• Novo Nordisk brings Ozempic to India for type 2 diabetes (The Week, December 2025): https://www.theweek.in/wire-updates/business/2025/12/12/dcm26-biz-novo-nordisk-diabetes.html
• Novo Nordisk launches Wegovy in India (Business Today, June 2025): https://www.businesstoday.in/amp/industry/pharma/story/novo-nordisk-launches-anti-obesity-drug-wegovy-in-india-at-rs-433625-per-dose-481578-2025-06-24
• WHO — obesity and overweight: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight